Kornimate/medical-research-clean huggingface dataset:
the effect of topical doxycycline gel on hba1c in patients with type 2 diabetes mellitus(dm) ®

Conditions: Diabetes Mellitus With Periodontal Disease

Summary: aim: the purpose of this study is to investigate the effect of nonsurgical periodontal therapy plus subgingivally doxycycline gel 3% on glycemic control in type 2 diabetes mellitus (type 2 dm) patients who have periodontitis. materials and methods: a total of 24 type 2 dm patients with periodontitis will be selected for the study, and randomly divided into two equal groups,who are at least 35 years of age and 16 teeth and type ii diabetes are (at least the last 3 months of diagnosis of diabetes and its fbs more than 110 have), and also with periodontal disease are chronic moderate (at least in three areas attachment level to a depth of 3-4 mm maxillary or mandibular been confirmed by clinical examination and radiographic signs are being); takes place. the initial hba1c patients should be between 7-9 percent over the past three months has changed his medication also found the necessary explanations on how to do that consent, plaque index (pi) by loe \& silness, bleeding on probing (bop) based on carter and barnes (if any bleeding number 1 and its absence is 0), probing depth (pd) and clinical attachment levels (cal) were recorded. "group 1": (12 patients) was treated with oral hygiene instruction, scaling and root planing, and doxycycline gel for 15 days; and "group 2": (12 patients) has the same treatment but with placebo gel, after 12 weeks their periodontal condition and fasting blood sugar (fbs), glycated hemoglobin (hba1c) level, will be reevaluated.

doxycycline downregulates the activity of matrix metalloproteinases (mmps), key destructive enzymes in periodontal disease

Eligibility criteria:
inclusion criteria: * patients with diabetes mellitus type ii (at least 3 months before diagnosis, and a fasting blood sugar level of more than 125 mg/dl) and has periodontal disease is a chronic moderate (has a clinical attachment level of 3-4 mm) peritonitis * minimum of 16 natural teeth, and no periodontal treatment in the prior 6 months, - had a glycated α hemoglobin (hba1c) value between 7- 9 percent at screening * had reported no changes in diabetes medications within the last 3 months were in the care of a physician for their diabetes. exclusion criteria: * pregnancy or lactation * history of allergy to drugs used in the study * smoking * diabetes-related emergency within 30 days ago * use of nonsteroidal anti-inflammatory drugs * or taking low dose daily aspirin (75-325 mg)\\ * use of immunosuppressive medications; antibiotic use * dialysis * risk of bleeding complications * the type of disease periodontal (aggressive) * a history of periodontal treatment in the previous 6 months * orthodontic treatment * using the removal prostheses * extensive dental caries * dental abscesses or infections.
validation of swedish short prom för venous insufficiency

Conditions: Superficial Venous Insufficiency; Quality of Life; Change After Treatment

Summary: validation of a new short swedish patient reported outcome measure for superficial venous insufficiency. analysis of its capacity to measure quality of life and its responsiveness to change caused by treatment.


Eligibility criteria:
inclusion criteria: * agrees to participate, diagnosed with superficial venous insufficiency c2-c6 exclusion criteria: * does not want to participate, less than c2, does not submit the answered questionnaires

Keywords: patient reported outcome measure
effect of phenytoin on the ganglion cell layer in patients with optic neuritis

Conditions: Optic Neuritis

Summary: optic neuritis typically occurs in young (mean age, 32 years), female (77%) patients, and it presents as subacute monocular visual loss that develops over several days. as yet, treatment with intravenous corticosteroid for optic neuritis had no long-term beneficial effect on vision. there are a number of factors that contribute to nerve fibre damage including increased level of sodium, so blocking sodium entry could help to protect them against damage. the main objective of the study is determine whether phenytoin (which blocks sodium entry) can protect nerve fibre and improve final visual function after optic neuritis.


Eligibility criteria:
inclusion criteria: * isolated, unilateral, first acute optic neuritis (confirmed by neuroophthalmologist) * willing to receive a steroidal regimen * no pathologic finding in first oct * no pathology and history of optic neuritis in contralateral eye * \<14 days since onset visual loss exclusion criteria: * contraindication or known allergy to phenytoin * use of a calcium channel or sodium channel blocker in the past 2 months * corticosteroid use in the past 2 months * pregnancy * significant cardiac, renal or liver abnormalities * prior clinical episode of optic neuritis in either eye * bilateral acute optic neuritis * known ocular or neurological conditions or abnormalities other than refractive error that impair visual function * refractive error of greater than +5 or -5 diopters * any condition that may interfere with performance of optical coherence tomography (oct): corneal, lens or fundoscopic abnormality, a co-morbid ocular condition not related to optic neuritis as detected on the oct reading
analysis of the levels of hladr+ extracellular vesicles in women with preeclampsia as a early potential biomarker

Conditions: Preeclampsia

Summary: analysis of the circulating levels of placenta-derived hla-dr+ extracellular vesicles in the first, second and third trimester of pregnancy of women with high and low risk to develop preeclampsia.

the aim of this study is to analyze the levels of circulating placenta-derived hla-dr+ extracellular vesicles in the first, second and third trimester of pregnancy of women with high and low risk to develop preeclampsia to investigate the potential role of hla-dr as early biomarker.

Eligibility criteria:
inclusion criteria: * pregnant women * aged \> 18 years exclusion criteria: * age \< 18 years * women unable to give informed consent * infectious diseases * twin pregnancies
evaluation of the clinical acceptance of soft contact lenses for myopia control

Conditions: Myopia

Summary: the main objective of the study was to evaluate the clinical acceptance of soft contact lenses for myopia control.

participants were randomized to wear each study contact lenses for 10 days with investigator and participant masking. the participants who are not contact lens wearer at enrollment wore single vision contact lenses for two weeks during the pre-investigation phase to get adapted to contact lens wear.

Eligibility criteria:
inclusion criteria: * age 10 to 16 years; * spectacle refraction: -0.75 to -6.00d spherical equivalent, maximum anisometropia 1.25d, cylinder up to -1.00dc * best corrected visual acuity of at least 20/25 in each eye. * parents/guardians and participant have read and understood the participant information sheet; * parents/guardians and participant have read, signed and dated the informed consent; * have normal eyes with the exception of the need for visual correction; * be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule. exclusion criteria: * ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear; * newly prescribed use of some systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator; * monocular participants (only one eye with functional vision) or participants fit with only one lens; * subjects with slit lamp findings greater than grade 1 (e.g. edema, infiltrates, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival, anterior segment inflammation) as per iso 11980, any previous history or signs of a contact lens related corneal inflammatory event (past corneal ulcers), or any other ocular abnormality that may contraindicate contact lens wear at the enrolment visit; * history of herpetic keratitis, ocular surgery or irregular cornea; * enrolment of the family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
the effect of magnesium oxide on plasma phosphate in hemodialysis patients

Conditions: Hyperphosphatemia

Summary: hyperphosphatemia is a common problem in hemodialysis (hd) patients. different chelators for control of hyperphosphatemia are used. the aim of this study was to assess the effect of magnesium oxide (mg oxide) on the control of serum phosphorus (p) level and evaluation of its side effects in hemodialysis patients.


Eligibility criteria:
inclusion criteria: hemodialysis with duration\>3 months serum p level \>5.5 mg/dl serum ca\>8 mg/dl. exclusion criteria: mg level \>3 mg/dl

Keywords: mg oxide hyperphosphatemia plasma phosphor level
assessment of grt6005 in painful osteoarthritis of the knee

Conditions: Osteoarthritis of the Knee

Summary: the purpose of the trial is to determine whether grt6005 is effective in patients with pain due to osteoarthritis of the knee.

the purpose of this study is to evaluate the safety, tolerability and efficacy of 3 doses of grt6005 taken once daily for 4 weeks in outpatients with moderate-to-severe painful osteoarthritis of the knee.

Eligibility criteria:
inclusion criteria: * painful osteoarthritis of the knee based on american college of rheumatology criteria * signed informed consent * on stable analgesic medications for painful osteoarthritis with regular analgesic intake for at least 3 months * pain intensity score of 4 or greater on the 11-point numeric rating scale (where 0 indicates "no pain" and 10 indicates "pain as bad as you can imagine"). exclusion criteria: * substance abuse * significant cardiac disease * presence of risk factors for torsades de pointes and chronic severe cardiac disease * history of seizure disorder * chronic gastrointestinal disease * conditions that contribute and confound to the assessment of pain * surgery or painful procedure during or within 3 months of enrollment * cancer * subjects with impaired renal function * subjects with impaired hepatic function * female subjects who are breastfeeding * history of chronic hepatitis b or c or human immunodeficiency virus infection, or presence of acute hepatitis a, b, or c within the past 3 months. * clinically relevant history of hypersensitivity or allergy to paracetamol, opioids or the excipients.

Keywords: osteoarthritis, knee analgesia pain painful
photoacoustic endoscopy in endometrial cancer

Conditions: Endometrial Cancer; Benign Neoplasm of Body of Uterus

Summary: the purpose of this research study is to evaluate whether a new technology called intrauterine photoacoustic endoscopy (pae) can be used to evaluate the inner lining of the uterus.

the investigators will evaluate whether this technology can be used and also try to obtain photoacoustic images and functional data (oxygen contents, blood vessel characteristics, etc) of the uterine lining to assess its appearance in women with and without cancer of the endometrium. currently, it is difficult for physicians to know whether or not tumors of the endometrium have invaded and spread to other organs without performing an extended surgery called a staging operation (removal of the lymph nodes or glands that drain the uterus to assess under the microscope whether or not the cancer has spread). our long term goal is to use this new photoacoustic (pa) technology to improve detection of occult metastatic disease. occult disease is defined as tumor which cannot be seen without the use of imaging techniques. and possibly avoid the need of extended operations. all of this could result in better care for patients with endometrial cancer and other gynecologic problems.

Eligibility criteria:
inclusion criteria: * women diagnosed with benign gynecologic pathology (n=10) or biopsy proven endometrial cancer (n=10) who will undergo hysterectomy. * participants must be ≥ 18 years of age. * subjects of reproductive potential must have a negative pregnancy test prior to study photoacoustic endoscopy procedure and hysterectomy. * subjects must be able understand and willing to sign a written informed consent form. exclusion criteria: * subjects with contraindications for general anesthesia or hysterectomy. * subjects with evidence of active pelvic inflammatory disease or purulent cervicitis. * subjects with prior endometrial ablation procedures. * gross tumoral involvement of the cervix or lower genital tract precluding cervical dilatation and endometrial sounding.

Keywords: photoacoustic endoscopy
amplify ep registry

Conditions: Atrial Fibrillation

Summary: an observational, prospective, multi-center, non-randomized registry designed to obtain real world clinical experience with the tactiflex catheter ablation system in the treatment of atrial fibrillation. patient assessments will occur at pre procedure and procedure, and 1 year post ablation


Eligibility criteria:
inclusion criteria: * patients who, in the opinion of the investigator, are candidates for ablation to treat atrial fibrillation. * plans to undergo an ablation procedure using the tactiflex ablation catheter™, sensor enabled™ (tactiflex se) manufactured by abbott. * de novo or redo af catheter ablation procedures. * able and willing to participate in baseline and all follow up evaluations. * 18 years of age or older. exclusion criteria: * enrolled in any other cardiac device clinical trial, investigational drug trial, or any other trial that may confound the results of the ablation procedure. * in the opinion of the investigator, any known contraindication to an ablation procedure or to any device or drug required for use during an ablation procedure as assessed by the investigator.

Keywords: ablation radiofrequency
ultrasound and x-ray in detecting articular cartilage calcification

Conditions: Chondrocalcinosis; Articular Cartilage Calcification

Summary: prospective study with an echography of the 2 knees and radiography of the 2 knees (front and profile) for each patient. if found calcification on ultrasound further examination with ultrasound wrists, hips and shoulders.

osteo-articular echography is currently recognized as an important development among rheumatologists. chondrocalcinosis, which can promote joint inflammation and cartilage degeneration, is highly prevalent in elderly subjects. osteo-articular echography is currently reconized as an important development among rheumatologists and can efficiently use to detect chondrocalcinosis. the aim of this study is to find a correlation between radiography and echography in detecting cppd crystal deposition, on a sample of patients and more important with a new generation of ultrasound with a probe superficial performance. 166 patients will be enrolled in this trial and an echography and a radiography of the 2 knees (front and profile) will be done for each patient. ih the echography show a calcification, further exams with wrists, hips shoulders echographies will be conducted. in case of liquid epanchement, analysis of the liquid will be carried in order to eliminate the differential diagnostic including septic arthritis

Eligibility criteria:
inclusion criteria: * patient\> 70 years * articular pathology of the knee * consent signed exclusion criteria: * not covered by social security

Keywords: inflammation of bone and cartilage
a study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction

Conditions: Lung Transplant Rejection

Summary: this double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive clad despite azithromycin therapy. study details include: the study duration will be up to 31 weeks for participants not entering the open-label extension (ole) period and up to 57 weeks for participants entering the ole period but not the long-term ole. the treatment duration will be up to 26 weeks for participants not entering the ole period and up to 52 weeks for participants entering the ole period but not the long-term ole. the number of visits will be up to 10 visits for participants not entering the ole period and up to 16 visits for participants entering the ole period but not the long-term ole. for participants who enter the long-term ole, treatment and study participation will continue with visits every 12 weeks per protocol specifications.


Eligibility criteria:
inclusion criteria: * participant ≥1 year post bilateral lung transplantation at the time of screening * participants presenting with clad stage 1 or 2: fev1 from \>50% to 80% of post-transplant baseline at screening and at randomization * participants who have received at least 8 weeks of azithromycin (≥250 mg/day, at least 3 times a week) prior to randomization exclusion criteria: * fev1 ≤50% of the post-transplant baseline value (clad 3 and 4) * lung function decline that can be explained by non-clad causes including but not limited to acute lung allograft rejection (\>a1), antibody-mediated rejection, airway stenosis, or tracheobronchomalacia
a clinical study for inactivated vaccine against ev71

Conditions: Enterovirus 71 Human

Summary: this study aims to evaluate the safety, reactogenicity and immunogenicity of ev71 vaccine in health children and infants aged from 2 months to \<12yrs.


Eligibility criteria:
main inclusion criteria: 1. healthy children and infants aged from 2 months to less than 12 years as established by medical history and clinical examination 2. the subjects' guardians are able to understand and sign the informed consent main exclusion criteria: 1. subject with previous known exposure to ev71. 2. subject with a history of herpangina or hand, foot and mouth disease associated with enterovirus infection in the past 3 months. 3. subject who was diagnosed with a significant neurological, pulmonary, cardiovascular, hematological, hepatic or renal disorder. 4. use of any investigational/non-registered product (including drug, vaccine and invasive medical device) within 30 days prior to vaccination or planned use during study period. 5. subject with any confirmed or suspected autoimmune disorder, or immunodeficiency 6. use of immunoglobulins or any blood products within 3 months prior to vaccination or planned use during the whole study period.

Keywords: ev71 vaccine
efficacy study of acupuncture to relieve symptoms of chronic prostatitis

Conditions: Prostatitis

Summary: limited evidence suggests that acupuncture may help relieve symptoms of chronic prostatitis/chronic pelvic pain syndrome. this study evaluated if acupuncture twice weekly for 10 weeks would help ameliorate symptoms of cp/cpps.

various studies have reported that this acupuncture able to relieve symptoms of chronic prostatitis (cp)/ chronic pelvic pain syndrome (cpps). however, controversy exists on the efficacy of this technique due to poor experimental designs and lack of placebo controls in these experiment. this study is the first randomised controlled study which will evaluate if acupuncture for 10 weeks will help improve symptoms of cp/cpps

Eligibility criteria:
inclusion criteria: * symptoms of discomfort or pain in the pelvic region for at least a three (3) months period within the last six (6) months. * moderate overall score on the nih-cpsi (overall score more than 15 out of a potential of 0-43 points) * diagnosed as having cpps category iii * participant is willing to undergo 10 weeks of acupuncture treatment exclusion criteria: * history of prostate, bladder or urethral cancer. * inflammatory bowel disease (such as crohn's disease or ulcerative colitis, but not irritable bowel syndrome). * undergone pelvic radiation or systemic chemotherapy, intravesical chemotherapy or intravesical bcg. * treated for unilateral orchialgia without pelvic symptoms. * active urethral stricture. * undergone turp, tuip, tuibn, tumt, tuna, balloon dilation of the prostate, open prostatectomy or any other prostate surgery or treatment such as cryotherapy or thermal therapy. * neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol. * liver disease. * diagnosed as acute or chronic bacterial prostatitis. * history of urinary tract infection positive uropathogen for the past year. * taking medications which could affect the lower urinary tract function * history of type 1 or 2 diabetes. * treated/currently undergoing treatment with acupuncture for any other illness including prostatitis for the past 6 months. * refusal to be needled or any form of bleeding disorder.

Keywords: prostatitis
fdfg versus smas flap after superficial parotidectomy; evaluation of functional and esthetic outcome

Conditions: Frey Syndrome

Summary: after parotidectomy, frey's syndrome and facial disfigurement are the most common encountered complications. free dermal fat graft (fdfg) and the superficial musculoaponeurotic system (smas) flap, have very promising results. in this study, the functional and esthetic outcome from their usage were compared.

parotidectomy is the standard procedure for treatment of many parotid lesions, however it carries a lot of drawbacks. facial asymmetry and frey's syndrome are the most annoying complications to the patients. insertion of inter-positioning grafts at parotidectomy bed can decrease these complications significantly. free dermal fat graft (fdfg) and the superficial musculoaponeurotic system (smas) flap, have very promising results. in this study the investigators have compared the functional and esthetic outcome from their usage. seventy-eight patient underwent parotidectomy for various causes. the patients were divided randomly in 2 groups each group 39 patients. in one group fdfg was inserted at the parotidectomy bed, while in the other group smas flap was performed. preoperative, operative, and postoperative data were recorded and analyzed. the normality of distribution of variables was verified by wilks -shapiro test. the data were expressed as number (no), percentage (%) mean (x̅) and standard deviation (sd). chi-square test (χ2) was used to study association between qualitative variables. whenever any of the expected cells were less than five, fischer's exact test was used. student's t-test is a test of significance used for comparison of quantitative variables between two groups of normally distributed data, while mann whitney's test was used for comparison of quantitative variables between two groups of not normally distributed data. two-sided p value was set to be significant if \< 0.05.

Eligibility criteria:
inclusion criteria: * patients indicated for superficial parotidectomy exclusion criteria: * less than 18 years of age * proved malignant parotid tumor

Keywords: frey's syndrome postparotidectomy reconstruction